Elicio Therapeutics EBIT

As of the most recent data (March 2026), ELTX shows a EBIT of $-38M. That compares with $-46M in the prior-year period — up 17.2% year over year. That is above the sector sector average of $-63M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ELTX's EBIT is now $-38M (was $-46M) — a 17.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Elicio Therapeutics is outperforming or lagging.

The its sector sector average EBIT is about $-63M. Elicio Therapeutics is at $-38M, which is higher that average. That is roughly 39.1% above the sector mean. Use the comparison chart on this page to see how ELTX stacks up against individual peers as well.

Tracking ELTX's ebit over time shows whether Elicio Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-38M That compares with $-46M in the prior-year period — up 17.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Elicio Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-38M) with ownership activity and broader fundamentals.